Obstetric strategies to reduce blindness from retinopathy of prematurity in infants born preterm

Gilbert, Clare; Dawes, Lisa; Wise, Michelle; Darlow, Brian A

doi:10.1111/aogs.13684

Cited by 5 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among these anti-VEGF drugs, razumab is a specific, recombinant humanized IgG1kappa homologous monoclonal antibody fragment with molecular weight 48kD, which has a strong affinity for all subtypes of VEGF [ 32 ]. Razumab can block VEGF-A quickly and for a long time, thus reducing vascular endothelial cell proliferation and vascular permeability, inhibiting angiogenesis and repairing the blood-retinal barrier [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

The Effects of Combuxil and Leizumab on Retinal Function and Serum Interleukin-17A in Premature Infants with Retinopathy

Ren

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To investigate the effects of Compaximab and raizumab on retinal function and serum interleukin-17A level in retinopathy of prematurity. Methods. Sixty cases of retinopathy of prematurity treated in our hospital from February 2019 to April 2021 were selected. The patients were randomly divided into control group ( n = 30 ) and research group ( n = 30 ). The control group was treated with Compaq and the research group was treated with razumab. The curative effect, retinal function, incidence of complications, intraocular pressure at different time, and the level of serum interleukin-17A were compared. Results. Compared with the two groups, the curative effect of the research group 93.33% (28/30) was greater than that of the control group 66.67% (20/30), and the difference was statistically significant ( P < 0.05 ). Compared with the incidence of complications, the incidence of corneal opacity, lens opacity, preretinal and vitreous hemorrhage, endophthalmitis, and traction retinal detachment in the research group was greatly lower, and the difference was statistically significant ( P < 0.05 ). Following the therapy, the IOP of the two groups decreased at different times. The IOP of 1 min, 10 min, and 30 min in the research group was obviously lower, and the difference was statistically significant ( P < 0.05 ). Following treatments, the levels of serum IL-17A were decreased. Compared with the control group, the level of serum IL-17A in the research group was greatly downregulated, and the difference was statistically significant ( P < 0.05 ). Conclusion. Intravitreal injection of razumab is an effective treatment for retinopathy of prematurity, which can effectively improve the retinal function of infants. The level of serum interleukin-17A can be reduced and intraocular pressure can be regulated, which is safe and effective.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effects of Combuxil and Leizumab on Retinal Function and Serum Interleukin-17A in Premature Infants with Retinopathy

Ren

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Ещё одна группа учёных подтвердила, что полный курс антенатальной терапии кортикостероидами ассоциировался с более низкой частотой каждой характеристики РН [31]. Проспективное когортное исследование 117 941 ребёнка показало, что дети, получавшие антенатальные кортикостероиды, имели более низкие показатели тяжёлой формы РН или смерти по сравнению с не получавшими кортикостероиды детьми на всех сроках беременности [38].…”

Section: использование лекарственных препаратов во время беременностиunclassified

Antenatal risk factors for retinopathy of premature

Макогон

Gorbacheva

Khlopkova

2023

Russian Pediatric Ophthalmology

View full text Add to dashboard Cite

This literature review presents the antenatal risk factors for the development of retinopathy of prematurity (ROP). Despite advances in antenatal and neonatal therapeutic interventions, screening, and follow-up, ROP remains a potentially vision-threatening retinopathy that requires careful monitoring and timely intervention to prevent the progression of adverse visual impairment or blindness. ROP is a multifactorial disease. The main risk factors are low gestational age and low birth weight. Recent experimental and clinical data support the hypothesis that multiple antenatal factors are involved in the etiology and progression of ROP. These factors include the age of the mother, maternal diseases, pregnancy-associated maternal pathologies, use of drugs to correct these conditions, and inflammatory process. Their roles are ambiguous and often contradictory. The physiology of the mother and placenta can significantly influence the risk of ROP development in preterm infants. The placenta connects the mothers body and the fetus, and it functions in the exchange of nutrients and oxygen between the mother and the fetus. Therefore, any pathological changes in the mothers body entail changes in the placenta, which this directly affects the fetus. A sudden loss of placental support is detrimental to the development of infants in the immediate postnatal period. Thus, these factors should be taken into account when assessing the risk of ROP development to predict and prevent poor vision in children.

show abstract

The association of various obstetric and perinatal factors with retinopathy of prematurity

et al. 2022

View full text Add to dashboard Cite

Obstetric strategies to reduce blindness from retinopathy of prematurity in infants born preterm

Cited by 5 publications

References 13 publications

The Effects of Combuxil and Leizumab on Retinal Function and Serum Interleukin-17A in Premature Infants with Retinopathy

The Effects of Combuxil and Leizumab on Retinal Function and Serum Interleukin-17A in Premature Infants with Retinopathy

Antenatal risk factors for retinopathy of premature

The association of various obstetric and perinatal factors with retinopathy of prematurity

Contact Info

Product

Resources

About